ClinicalTrials.gov
ClinicalTrials.gov Menu

Blood Pressure Assessment in Atrial Fibrillation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01088269
Recruitment Status : Recruiting
First Posted : March 17, 2010
Last Update Posted : September 14, 2017
Sponsor:
Information provided by (Responsible Party):
George S. Stergiou, University of Athens

March 16, 2010
March 17, 2010
September 14, 2017
March 2010
December 2017   (Final data collection date for primary outcome measure)
Blood Pressure Measurement in Atrial Fibrillation,Serum Markers and echocardiographic indexes in atrial fibrillation (AF) [ Time Frame: Baseline ]
  1. Evaluation of the oscillometric technique of an electronic device in blood pressure measurement.
  2. Evaluation of the relationship of blood pressure levels with serum markers and ultrasonographic cardiac indexes.
  3. Evaluation of a 24h ambulatory blood pressure monitoring device (Microlife WatchBPO3) in terms of its diagnostic value for the detection of atrial fibrillation compared with the reference 24h Holter ECG
Blood Pressure Measurement in Atrial Fibrillation,Serum Markers and echocardiographic indexes in AF [ Time Frame: Baseline ]
  1. Evaluation of the oscillometric technique of an electronic device in blood pressure measurement.
  2. Evaluation of the relationship of blood pressure levels with serum markers and ultrasonographic cardiac indexes.
Complete list of historical versions of study NCT01088269 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Blood Pressure Assessment in Atrial Fibrillation
Evaluation of the Oscillometric Blood Pressure Measurement in Atrial Fibrillation and Relation of Blood Pressure With Serum Biomarkers and Echocardiographic Indexes

This is a cross-sectional study including patients with permanent atrial fibrillation. Assessment will include:

  • clinic blood pressure measurements (mercury sphygmomanometer and automated oscillometric device)
  • 24-hour ambulatory blood pressure monitoring
  • determination of various serum markers and cardiac ultrasound.
  • evaluation of a 24h ambulatory blood pressure monitoring device (Microlife WatchBPO3) in terms of its diagnostic value for the detection of atrial fibrillation compared with the reference 24h Holter ECG
Not Provided
Observational
Observational Model: Case-Control
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample
SUBJECTS REFERRED TO HYPERTENSION CENTER
Atrial Fibrillation
Not Provided
  • AF
    Hypertensive patients in AF
  • Non-AF
    Hypertensive Patients
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
100
70
December 2017
December 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Hypertensives adults in atrial fibrillation

Exclusion Criteria:

  • Renal disease (Cr > 2 mg/l).
  • Patients with pacemaker rhythm during the study.
  • Each patient with acute disease (inflammation, surgery), malignancy, collagen diseases, pulmonary fibrosis, renal failure, liver failure, chronic inflammatory diseases.
Sexes Eligible for Study: All
25 Years to 85 Years   (Adult, Senior)
No
Contact: George S Stergiou, MD +302107763117 gstergi@med.uoa.gr
Greece
 
 
NCT01088269
BPM IN AF
No
Not Provided
Not Provided
George S. Stergiou, University of Athens
University of Athens
Not Provided
Study Chair: George S Stergiou, MD Hypertension Center,Third Department of Medicine,University of Athens,Greece
University of Athens
September 2017